TrialPanorama/TrialPanorama-database huggingface dataset:
Study: 2188239
Drug: Permethrin 5%
Normalized name: PERMETHRIN 5% CREAM
Approvals — FDA: no, EMA: no, PMDA: no
Description: Permethrin 5% cream (Elimite)
Study: 2188239
Drug: Crotamiton 10%
Normalized name: CROTAMITON 10% LOTION
Approvals — FDA: no, EMA: no, PMDA: no
Description: Crotamiton 10% cream (Eurax)
Study: 22594116
Drug: Western medicine
Normalized name: Medicaine Sting
Approvals — FDA: no, EMA: no, PMDA: no
Description: Western medicine (Group E)
Study: 26227279
Drug: Reduced glycerin
Normalized name: Glycerin
DrugBank: Glycerin (DB09462)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Reduced glycerin vaginal formulation (RGVF)
Study: 26227279
Drug: Isoosmolal rectal-specific
Normalized name: Pacific halibut
DrugBank: Pacific halibut (DB10616)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Isoosmolal rectal-specific formulation (RF)
Study: 25005333
Drug: Calcium-vitamin D
Normalized name: Calcium-Vitamin D
Approvals — FDA: no, EMA: no, PMDA: no
Description: Calcium-vitamin D co-supplementation (50,000 U/week vitamin D + 1,000 mg/day calcium)
Study: 22390325
Drug: Eye patches
Normalized name: CAMPHOR, (-)- 1 g in 24 g TOPICAL PATCH [Eye Patches]
Approvals — FDA: no, EMA: no, PMDA: no
Description: Eye patches (four main brands)
Study: 20533214
Drug: Vitamin C
Normalized name: Vitamin C
DrugBank: Sodium ascorbate (DB14482)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Vitamin C (250 mg every other day for 12 weeks)
Study: 15080373
Drug: Perindopril (4
Approvals — FDA: no, EMA: no, PMDA: no
Description: Perindopril (4 mg daily) with or without indapamide (2 mg daily)
Study: 2782470
Drug: Standard treatment
Approvals — FDA: no, EMA: no, PMDA: no
Description: Standard treatment (hospital milieu therapy, pharmacotherapy, clinical management sessions)
Study: 7034157
Drug: Endoscopic YAG-laser
Approvals — FDA: no, EMA: no, PMDA: no
Description: Endoscopic YAG-laser treatment
Study: 7034157
Drug: Endoscopic YAG-laser
Approvals — FDA: no, EMA: no, PMDA: no
Description: Endoscopic YAG-laser treatment vs Control group
Study: 24061999
Drug: Erythromycin (0.25
Approvals — FDA: no, EMA: no, PMDA: no
Description: Erythromycin (0.25 g tid po for 1 week)
Study: 3735482
Drug: NaHCO3 0.15
Normalized name: NaHCO3 0.15 MEQ/ML Injectable Solution
Approvals — FDA: no, EMA: no, PMDA: no
Description: NaHCO3 0.15 g per kg body weight
Study: 3735482
Drug: NaHCO3 0.30
Approvals — FDA: no, EMA: no, PMDA: no
Description: NaHCO3 0.30 g per kg body weight
Study: 31427292
Drug: Piperacillin-tazobactam (TZP)
Normalized name: piperacillin / tazobactam
Approvals — FDA: no, EMA: no, PMDA: no
Description: Piperacillin-tazobactam (TZP) 75 mg/kg every 4 h infused over 0.5 h for infants ages 2 to <6 months
Study: 31427292
Drug: Piperacillin-tazobactam (TZP)
Normalized name: piperacillin / tazobactam
Approvals — FDA: no, EMA: no, PMDA: no
Description: Piperacillin-tazobactam (TZP) 130 mg/kg every 8 h infused over 4 h for children ages >6 months to 6 years
Study: 31324600
Drug: Adverse events
Normalized name: iodine
DrugBank: Iodine (DB05382)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Adverse events during treatment
Study: 28725956
Drug: Child‐ and
Approvals — FDA: no, EMA: no, PMDA: no
Description: Child‐ and Family‐Focused Cognitive‐Behavioral Therapy (CFF‐CBT)
Study: 12416945
Drug: Cardioselective β-blocker
Normalized name: capsaicin
DrugBank: Capsaicin (DB06774)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Cardioselective β-blocker (continued treatment) in patients with COPD
Study: 10220232
Drug: Overall costs
Normalized name: costus root oil
Approvals — FDA: no, EMA: no, PMDA: no
Description: Overall costs for all agents except chlorthalidone
Study: 3328986
Drug: Adjuvant tamoxifen
Approvals — FDA: no, EMA: no, PMDA: no
Description: Adjuvant tamoxifen (40 mg daily for 2 years)
Study: 7191298
Drug: 80 mg
Normalized name: RNA 180 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 80 mg oxprenolol twice a day
Study: 7191298
Drug: 160 mg
Normalized name: nadolol 160 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 160 mg slow-release oxprenolol once a day
Study: 31227466
Drug: Ultrasound-guided single-dose
Approvals — FDA: no, EMA: no, PMDA: no
Description: Ultrasound-guided single-dose interscalene block (USG SDIB)
Study: 28961662
Drug: Citalopram monotherapy
Approvals — FDA: no, EMA: no, PMDA: no
Description: Citalopram monotherapy (DOCS group)
Study: 23842022
Drug: Paliperidone (up
Approvals — FDA: no, EMA: no, PMDA: no
Description: Paliperidone (up to 9 mg/d)
Study: 22544579
Drug: Bevacizumab maintenance
Normalized name: Bevacizumab
DrugBank: Bevacizumab (DB00112)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: Bevacizumab maintenance every 21 days after initial treatment with bevacizumab 15 mg/kg, pemetrexed 500 mg/m², and carboplatin AUC 6 every 21 days for 6 cycles.
Study: 22544579
Drug: Treatment-related grade
Normalized name: Hongo Killer Treatment
Approvals — FDA: no, EMA: no, PMDA: no
Description: Treatment-related grade 3/4 toxicities during initial treatment.
Study: 25311306
Drug: RT plus
Normalized name: Recort Plus
Approvals — FDA: no, EMA: no, PMDA: no
Description: RT plus PCV chemotherapy
Study: 11696471
Drug: Warfarin therapy
Approvals — FDA: no, EMA: no, PMDA: no
Description: Warfarin therapy (group W)
Study: 11696471
Drug: Warfarin therapy
Approvals — FDA: no, EMA: no, PMDA: no
Description: Warfarin therapy (subject A)
Study: 22918094
Drug: Oral tramadol
Approvals — FDA: no, EMA: no, PMDA: no
Description: Oral tramadol
Study: 31597591
Drug: Support package
Approvals — FDA: no, EMA: no, PMDA: no
Description: Support package including a website, printed booklet, and cognitive-behavioral therapy-based sessions delivered by a qualified practitioner
Study: 28623947
Drug: digital automated
Approvals — FDA: no, EMA: no, PMDA: no
Description: digital automated CBT‐I delivered by a web and/or mobile platform (in addition to treatment as usual (TAU))
Study: 27575673
Drug: Inhalation aromatherapy
Normalized name: isopropyl alcohol
DrugBank: Isopropyl alcohol (DB02325)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Inhalation aromatherapy
Study: 21277704
Drug: Standard Clinic
Approvals — FDA: no, EMA: no, PMDA: no
Description: Standard Clinic Treatment (ST)
Study: 16483155
Drug: Sperm concentration
Normalized name: herring sperm DNA
Approvals — FDA: no, EMA: no, PMDA: no
Description: Sperm concentration > 20 x 10(6)/ml
Study: 25520332
Drug: Micafungin 100
Normalized name: micafungin 100 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Micafungin 100 mg
Study: 1385919
Drug: Bupivacaine with
Approvals — FDA: no, EMA: no, PMDA: no
Description: Bupivacaine with morphine (group B)
Study: 6741887
Drug: Rehearsal preparation
Normalized name: cranberry preparation
Approvals — FDA: no, EMA: no, PMDA: no
Description: Rehearsal preparation procedure
Study: 6741887
Drug: Usual preparation
Normalized name: cranberry preparation
Approvals — FDA: no, EMA: no, PMDA: no
Description: Usual preparation (Control)
Study: 21135531
Drug: Nonpharmacological therapy
Normalized name: Monistat Simple Therapy
Approvals — FDA: no, EMA: no, PMDA: no
Description: Nonpharmacological therapy (holistic cognitive rehabilitation program)
Study: 19799537
Drug: β-blockers (premedication)
Normalized name: capsaicin
DrugBank: Capsaicin (DB06774)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: β-blockers (premedication)
Study: 11822997
Drug: Mirtazapine (15
Approvals — FDA: no, EMA: no, PMDA: no
Description: Mirtazapine (15 mg at bedtime, titrated to 30 mg if needed)
Study: 7723155
Drug: Aggressive medical
Normalized name: ZO SKIN HEALTH Aggressive Anti-Aging Program KIT
Approvals — FDA: no, EMA: no, PMDA: no
Description: Aggressive medical management (daily aspirin and risk factor management)
Study: 6458577
Drug: 0.5% topical
Normalized name: Carac 0.5% Topical Cream
Approvals — FDA: no, EMA: no, PMDA: no
Description: 0.5% topical thymoxamine hydrochloride
Study: 28473213
Drug: Topical ice
Normalized name: Camphor Ice Topical Product
Approvals — FDA: no, EMA: no, PMDA: no
Description: Topical ice slush cooling
Study: 21838789
Drug: BAY 60‐5521
Approvals — FDA: no, EMA: no, PMDA: no
Description: BAY 60‐5521 (25 mg)
Study: 21838789
Drug: BAY 60‐5521
Approvals — FDA: no, EMA: no, PMDA: no
Description: BAY 60‐5521 (50 mg)
Study: 21838789
Drug: BAY 60‐5521
Approvals — FDA: no, EMA: no, PMDA: no
Description: BAY 60‐5521 (all doses)
Study: 10493456
Drug: 600 mg
Normalized name: mesna 600 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 600 mg ipriflavone daily for 12 months
Study: 10493456
Drug: 1 microg
Normalized name: Alpha 1 microglobulin
Approvals — FDA: no, EMA: no, PMDA: no
Description: 1 microg vitamin D3 daily for 12 months
Study: 8672854
Drug: Taxotere (docetaxel)
Normalized name: Docetaxel
DrugBank: Docetaxel (DB01248)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Taxotere (docetaxel) at 100 mg/m2 administered in 1 hour perfusion every 21 days
Study: 8672854
Drug: CPT 11
Approvals — FDA: no, EMA: no, PMDA: no
Description: CPT 11 (irinotecan) at 350 mg/m2 every three weeks
Study: 8672854
Drug: CPT 11
Approvals — FDA: no, EMA: no, PMDA: no
Description: CPT 11 (irinotecan) at 500 mg/m2 with drug support against diarrhea
Study: 1838693
Drug: 5 mg
Normalized name: talc 25 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 5 mg cilazapril
Study: 6635104
Drug: 50 mg
Normalized name: talc 50 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 50 mg hydrochlorothiazide + 5 mg amiloride (control group)
Study: 19160103
Drug: Oral brush
Normalized name: povidone-iodine
DrugBank: Povidone-iodine (DB06812)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Oral brush biopsy (OralCDx)
Study: 17174102
Drug: Disulfiram (DIS)
Normalized name: Disulfiram
DrugBank: Disulfiram (DB00822)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Disulfiram (DIS) 400mg daily + Cognitive Behaviour Therapy (CBT)
Study: 11786588
Drug: 1-hour infusion
Normalized name: coagulation factor IX recombinant immunoglobulin G1 fusion protein 1 UNT [Alprolix]
Approvals — FDA: no, EMA: no, PMDA: no
Description: 1-hour infusion of paclitaxel 100 mg/m2
Study: 3289947
Drug: felodipine 5
Normalized name: felodipine 5 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: felodipine 5 mg b.i.d. in addition to HCTZ 25 mg o.m.
Study: 3289947
Drug: propranolol 80
Normalized name: propranolol 80 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: propranolol 80 mg b.i.d. in addition to HCTZ 25 mg o.m.
Study: 24045883
Drug: Modafinil (300
Approvals — FDA: no, EMA: no, PMDA: no
Description: Modafinil (300 mg/d)
Study: 19716589
Drug: Sperm treatment
Normalized name: herring sperm DNA
Approvals — FDA: no, EMA: no, PMDA: no
Description: Sperm treatment with exogenous platelet-activating factor (PAF)
Study: 19716589
Drug: No sperm
Normalized name: herring sperm DNA
Approvals — FDA: no, EMA: no, PMDA: no
Description: No sperm treatment with exogenous platelet-activating factor (PAF)
Study: 15612842
Drug: Couples alcohol‐focused
Approvals — FDA: no, EMA: no, PMDA: no
Description: Couples alcohol‐focused treatment
Study: 15671806
Drug: 1 g
Normalized name: Molds 1 g
Approvals — FDA: no, EMA: no, PMDA: no
Description: 1 g of azithromycin
Study: 9269606
Drug: 500 mg
Normalized name: bran 500 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 500 mg of ciprofloxacin
Study: 8324868
Drug: 0.15 mg/kg
Approvals — FDA: no, EMA: no, PMDA: no
Description: 0.15 mg/kg intravenous ondansetron
Study: 8324868
Drug: 0.30 mg/kg
Approvals — FDA: no, EMA: no, PMDA: no
Description: 0.30 mg/kg intravenous ondansetron
Study: 8324868
Drug: 0.015 mg/kg
Approvals — FDA: no, EMA: no, PMDA: no
Description: 0.015 mg/kg intravenous ondansetron
Study: 23419735
Drug: No statin
Approvals — FDA: no, EMA: no, PMDA: no
Description: No statin therapy (Control)
Study: 24785989
Drug: Solifenacin 5
Normalized name: solifenacin 5 mg oral tablet
Approvals — FDA: no, EMA: no, PMDA: no
Description: Solifenacin 5 mg, 6 hours before surgery and 5 mg per day after surgery for 2 weeks
Study: 21501692
Drug: CIC‐HFA 148
Approvals — FDA: no, EMA: no, PMDA: no
Description: CIC‐HFA 148 μg
Study: 15238279
Drug: 2 mg
Normalized name: iodine 2 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 2 mg copper/L
Study: 15238279
Drug: > 6
Normalized name: {70 (10 ML delandistrogene moxeparvovec-rokl 13300000000000 VECTOR-GENOMES/ML Injection [Elevidys]) } Pack [Elevidys Kit > 69.5 KG]
Approvals — FDA: no, EMA: no, PMDA: no
Description: > 6 mg copper/L
Study: 15238279
Drug: < 0.01
Approvals — FDA: no, EMA: no, PMDA: no
Description: < 0.01 mg copper/L (control)
Study: 2689970
Drug: Ventilatory muscle
Normalized name: ActivOn Joint & Muscle
Approvals — FDA: no, EMA: no, PMDA: no
Description: Ventilatory muscle endurance training (breathing through an inspiratory resistor equivalent to 85% SIP for 15 minutes twice daily, 5 days a week for 8 weeks)
Study: 31405532
Drug: Stretching regimen
Normalized name: Anacin Aspirin Regimen Pill
Approvals — FDA: no, EMA: no, PMDA: no
Description: Stretching regimen (three daily exercises to stretch the calves and hamstrings)
Study: 9476695
Drug: Caffeine (0,
Approvals — FDA: no, EMA: no, PMDA: no
Description: Caffeine (0, 50, or 100 mg per hour for 5 hours, total of 0, 250, or 500 mg)
Study: 7885978
Drug: Ampicillin-sulbactam 3
Normalized name: ampicillin / sulbactam
Approvals — FDA: no, EMA: no, PMDA: no
Description: Ampicillin-sulbactam 3 g
Study: 2745258
Drug: Cefoxitin 2
Normalized name: cefoxitin 2000 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Cefoxitin 2 g
Study: 16929626
Drug: Deaf individuals
Normalized name: chloroxylenol
DrugBank: Chloroxylenol (DB11121)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Deaf individuals (bilingual, nasal-breathing, bilingual, buccal-breathing, oralist, nasal-breathing)
Study: 11153591
Drug: 0.5 g
Normalized name: Gelatin Capsules, 10.5 gr
Approvals — FDA: no, EMA: no, PMDA: no
Description: 0.5 g alcohol x kg body weight consumed 90 min prior to sleep time
Study: 2442552
Drug: Lisinopril (20-80
Approvals — FDA: no, EMA: no, PMDA: no
Description: Lisinopril (20-80 mg/day)
Study: 11349617
Drug: Nifedipine (40-80
Approvals — FDA: no, EMA: no, PMDA: no
Description: Nifedipine (40-80 mg/day)
Study: 31600823
Drug: Potentially misclassified
Normalized name: Potentilla discolor whole extract
Approvals — FDA: no, EMA: no, PMDA: no
Description: Potentially misclassified intrapartum stillbirths (180) with birthweight less than 2500 g.
Study: 18928092
Drug: Suhuang Zhike
Normalized name: MENTHOL 4.3 g / METHYL SALICYLATE 9.4 g TOPICAL OIL [Shuang Long Pain Relieving Oil]
Approvals — FDA: no, EMA: no, PMDA: no
Description: Suhuang Zhike Capsule (SZC), 3 capsules three times daily for 7 days
Study: 18928092
Drug: Zhike Ningsuo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Zhike Ningsuo Capsule (ZNC), 3 capsules three times daily for 7 days
Study: 12736566
Drug: Treatment B
Normalized name: PanOxyl Acne Treatment Bar
Approvals — FDA: no, EMA: no, PMDA: no
Description: Treatment B (FT + TAM 20 mg/day for 2 years)
Study: 8969280
Drug: Diet B
Approvals — FDA: no, EMA: no, PMDA: no
Description: Diet B (50 g protein/d)
Study: 1482268
Drug: verapamil 240
Normalized name: verapamil 240 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: verapamil 240 mg SR (V)
Study: 1482268
Drug: nifedipine 20
Normalized name: nifedipine 20 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: nifedipine 20 mg SR (N)
Study: 4006378
Drug: Oral pseudoracemic
Approvals — FDA: no, EMA: no, PMDA: no
Description: Oral pseudoracemic verapamil (160 mg)
Study: 27724916
Drug: Robot-assisted therapy
Normalized name: Monistat Simple Therapy
Approvals — FDA: no, EMA: no, PMDA: no
Description: Robot-assisted therapy
Study: 27978944
Drug: Upstream antithrombotic
Approvals — FDA: no, EMA: no, PMDA: no
Description: Upstream antithrombotic treatment
Study: 20693157
Drug: Lifibrol (600
Approvals — FDA: no, EMA: no, PMDA: no
Description: Lifibrol (600 mg/d)
Study: 11742880
Drug: Pravastatin (40
Approvals — FDA: no, EMA: no, PMDA: no
Description: Pravastatin (40 mg/d)
Study: 10582873
Drug: 600 mg
Normalized name: mesna 600 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 600 mg of azithromycin daily for 6 weeks
Study: 10582873
Drug: 1,200 mg
Normalized name: lecithin 1,200 mg ORAL CAPSULE
Approvals — FDA: no, EMA: no, PMDA: no
Description: 1,200 mg of azithromycin daily for 6 weeks
Study: 1831017
Drug: 75 micrograms
Approvals — FDA: no, EMA: no, PMDA: no
Description: 75 micrograms of intravenous fentanyl intraoperatively
Study: 6120763
Drug: Lorazepam (4
Approvals — FDA: no, EMA: no, PMDA: no
Description: Lorazepam (4 to 10 mg IV)
Study: 6120763
Drug: Clonazepam (1
Approvals — FDA: no, EMA: no, PMDA: no
Description: Clonazepam (1 mg IV)
Study: 17631800
Drug: Yiqi Tongmai
Approvals — FDA: no, EMA: no, PMDA: no
Description: Yiqi Tongmai Oral Liquid (YQTM)
Study: 17631800
Drug: Shuxin Oral
Approvals — FDA: no, EMA: no, PMDA: no
Description: Shuxin Oral Liquid (SX)
Study: 15675261
Drug: Both anesthetic
Normalized name: Gelato Anesthetic
Approvals — FDA: no, EMA: no, PMDA: no
Description: Both anesthetic solutions
Study: 17994292
Drug: alpha-tocopherol (50
Approvals — FDA: no, EMA: no, PMDA: no
Description: alpha-tocopherol (50 mg/day)
Study: 17994292
Drug: beta-carotene (20
Approvals — FDA: no, EMA: no, PMDA: no
Description: beta-carotene (20 mg/day)
Study: 9579716
Drug: roxithromycin 300
Normalized name: roxithromycin 300 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: roxithromycin 300 mg po od
Study: 9579716
Drug: clarithromycin 500
Normalized name: clarithromycin 500 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: clarithromycin 500 mg po bd
Study: 2650586
Drug: Clemastine tablet
Normalized name: clemastine Oral Tablet
DrugBank: Clemastine (DB00283)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Clemastine tablet
Study: 28695477
Drug: Combined treatment
Normalized name: Hongo Killer Treatment
Approvals — FDA: no, EMA: no, PMDA: no
Description: Combined treatment of xylometazoline and dexpanthenol
Study: 28695477
Drug: Xylometazoline monotherapy
Normalized name: XYLOMETAZOLINE
DrugBank: Xylometazoline (DB06694)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Xylometazoline monotherapy
Study: 21679262
Drug: HCV treatment
Normalized name: Hongo Killer Treatment
Approvals — FDA: no, EMA: no, PMDA: no
Description: HCV treatment eligibility
Study: 12131885
Drug: Sterile water
Normalized name: sterile water
DrugBank: Water (DB09145)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Sterile water irrigation with One-Step bonding agent
Study: 12131885
Drug: 0.9% NaCl
Normalized name: Trace Metals Additive in 0.9% NaCl
Approvals — FDA: no, EMA: no, PMDA: no
Description: 0.9% NaCl irrigation with One-Step bonding agent
Study: 12131885
Drug: Normal saline
Normalized name: Normal Saline Flush
Approvals — FDA: no, EMA: no, PMDA: no
Description: Normal saline irrigation with One-Step bonding agent
Study: 12131885
Drug: Normal saline
Normalized name: Normal Saline Flush
Approvals — FDA: no, EMA: no, PMDA: no
Description: Normal saline irrigation with Solo bonding agent
Study: 29396219
Drug: Nutrition intervention
Normalized name: Ocean Blue Nutritionals Omega-3 1450 Pill
Approvals — FDA: no, EMA: no, PMDA: no
Description: Nutrition intervention (counselling on appropriate maternal, infant, and young child feeding plus small-quantity lipid-based nutrient supplements from 6-24 months)
Study: 8534483
Drug: Inhaled beclomethasone
Normalized name: beclomethasone Inhalant Product
Approvals — FDA: no, EMA: no, PMDA: no
Description: Inhaled beclomethasone dipropionate (BDP) 500 micrograms twice daily for 4 months
Study: 1810682
Drug: Captopril 25
Normalized name: captopril 25 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Captopril 25 mg sublingually after 1 hour of nitroglycerin (3 mg/h) and heparin (1200 IU/h) infusion
Study: 30633040
Drug: Daily oral
Normalized name: GEMTESA 75 MG Once-Daily Oral Tablet
Approvals — FDA: no, EMA: no, PMDA: no
Description: Daily oral tablet
Study: 3306290
Drug: Org OD
Normalized name: ORG-34517
DrugBank: ORG-34517 (DB05423)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Org OD 14 (2.5 mg/day)
Study: 22348981
Drug: Coated implants
Normalized name: Drug Implant
Approvals — FDA: no, EMA: no, PMDA: no
Description: Coated implants with a thin fibrinogen layer containing 2 bisphosphonates
Study: 22348981
Drug: Untreated implants
Normalized name: benzoyl peroxide
DrugBank: Benzoyl peroxide (DB09096)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Untreated implants
Study: 18265662
Drug: Lamivudine monotherapy
Normalized name: Lamivudine
DrugBank: Lamivudine (DB00709)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: Lamivudine monotherapy after combination therapy
Study: 18265662
Drug: Long-term antiviral
Normalized name: benzethonium
DrugBank: Benzethonium (DB11125)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Long-term antiviral maintenance therapy
Study: 11196521
Drug: Chondroitin sulfate
Normalized name: Chondroitin Sulfate
DrugBank: Chondroitin sulfate (DB09301)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Chondroitin sulfate (CS) 1 g/day
Study: 2816360
Drug: Recombinant human
Normalized name: Recombinant human TNF
DrugBank: Etanercept (DB00005)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: Recombinant human growth hormone (rhGH) treatment for 6 months
Study: 1215880
Drug: Heparin in
Normalized name: heparin Injection
Approvals — FDA: no, EMA: no, PMDA: no
Description: Heparin in males
Study: 1215880
Drug: Heparin in
Normalized name: heparin Injection
Approvals — FDA: no, EMA: no, PMDA: no
Description: Heparin in females
Study: 1215880
Drug: Heparin in
Normalized name: heparin Injection
Approvals — FDA: no, EMA: no, PMDA: no
Description: Heparin in patients under 60 years
Study: 1215880
Drug: Heparin in
Normalized name: heparin Injection
Approvals — FDA: no, EMA: no, PMDA: no
Description: Heparin in patients with predisposing factors
Study: 31390762
Drug: Combined synbiotics
Normalized name: combinations
Approvals — FDA: no, EMA: no, PMDA: no
Description: Combined synbiotics and BCAAs treatment
Study: 23507791
Drug: 20 mg
Normalized name: urea 20 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 20 mg triamcinolone acetonide (low-dose group, n = 20)
Study: 21499192
Drug: Intravitreal injection
Normalized name: Eylea 2 MG per 0.05 ML Intravitreal Injection
Approvals — FDA: no, EMA: no, PMDA: no
Description: Intravitreal injection of bevacizumab (1.25 mg) 1 week before vitrectomy
Study: 19335800
Drug: 10 mg
Normalized name: biotin 10 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 10 mg lidocaine hydrochloride 10% spray
Study: 1914480
Drug: Selective parenteral
Approvals — FDA: no, EMA: no, PMDA: no
Description: Selective parenteral and enteral antisepsis regimen (oral nonabsorbable antimicrobial agents: polymyxin E, gentamicin, and amphotericin B; parenteral cefotaxime)
Study: 19649577
Drug: Skeletal anchorage
Normalized name: Spongia officinalis skeleton extract
Approvals — FDA: no, EMA: no, PMDA: no
Description: Skeletal anchorage via mini-implants in the anterior palate
Study: 17301557
Drug: TMC114/r 600/100
Approvals — FDA: no, EMA: no, PMDA: no
Description: TMC114/r 600/100 mg twice daily
Study: 7880228
Drug: Atovaquone (750
Approvals — FDA: no, EMA: no, PMDA: no
Description: Atovaquone (750 mg orally with meals three times daily for 21 days)
Study: 8588062
Drug: Serotonin reuptake
Normalized name: Selective serotonin reuptake inhibitors
Approvals — FDA: no, EMA: no, PMDA: no
Description: Serotonin reuptake inhibitors
Study: 12668373
Drug: Other antidepressants
Normalized name: Other antidepressants
Approvals — FDA: no, EMA: no, PMDA: no
Description: Other antidepressants
Study: 17086007
Drug: Pharmaceutical agents
Normalized name: PHARMACEUTICAL GLAZE
Approvals — FDA: no, EMA: no, PMDA: no
Description: Pharmaceutical agents for chronic disease management
Study: 17086007
Drug: COX-2 anti-inflammatory
Normalized name: Surpass Anti-Inflammatory
Approvals — FDA: no, EMA: no, PMDA: no
Description: COX-2 anti-inflammatory drugs